Skip to content

BigHat Biosciences — AI platform for designing antibody therapeutics

Recently funded· $75M Series C· September 26, 2026

BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.

Get it by email

Companies like BigHat Biosciences go out every weekday morning. One-click unsubscribe.

Agent? Subscribe over MCP

Round
$75M Series C
Logged
September 26, 2026, in issue #39

More in biotechnology

BigHat Biosciences went out in issue #39, with 14 other picks.